君实生物 · Junshi Biosciences
← News archive

· Regulatory update

China accepts subcutaneous toripalimab applications covering 12 indications

Junshi announced that China’s National Medical Products Administration had accepted applications for the subcutaneous formulation of toripalimab, known as JS001sc.

The March announcement concerned regulatory review across 12 oncology indications.

Read the full company release